
TB-500 5mg (Thymosin Beta-4)
Research Use Only
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Purity / Result
99.05% average
Mass / Quantity
4.98 mg average
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
TB-500 is the active domain of Thymosin Beta-4 (TB-4), with a primary role as an actin binding protein. Its amino acid sequence is Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser. Research demonstrates TB-500 encourages nervous system tissue repair and remodeling by activating oligodendrocytes, is a potent stimulator of VEGF expression for capillary growth, promotes hair growth through increased hair follicle numbers and grouping, enhances antibiotic effects synergistically when combined with ciprofloxacin, promotes cardiovascular recovery through collateral blood vessel growth and reduced fibrosis following heart attack, and enhances autophagy as a protective mechanism against neurodegenerative diseases. This 5mg vial provides material for tissue repair and regenerative biology research.
Frequently Bought Together

TB-500 5mg
5mg
$29 USD
Bundle & Save
$64 USD
Save $4 USD
$109 USD
Save $9 USD
$154 USD
Save $24 USD
$189 USD
Save $39 USD
Click any product above to toggle selection
Related Peptides
What Is TB-500?
TB-500 is a 43 amino acid synthetic analogue of thymosin beta-4 (TB-4), which is found naturally in nearly all mammalian cells. TB-500 is known for its effects on actin protein, cell migration, and wound healing. TB-500 has been shown in animal models and in vitro studies to improve blood vessel growth, accelerate wound healing, decrease inflammation, and promote extracellular matrix production. The peptide is under current investigation for its ability to reduce oxidative stress in spinal cord injury, improve recovery following heart attack, and for its many anti-aging effects.
TB-500 Peptide Structure

| Sequence | Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser |
| Molecular Formula | C212H350N56O78S |
| Molecular Weight | 4963.44 g/mol |
| CAS Number | 77591-33-4 |
| PubChem CID | 16132341 |
TB-500 Mechanism of Action
TB-500 is the active domain of TB-4, which has a primary role as an actin binding protein. Actin is a critical component of cell structure and makes up microfilaments. Microfilaments are responsible for giving cells their shape, protecting the integrity of cell membranes, allowing cells to move/migrate, and certain steps in cellular reproduction. Actin is also one of the primary components of muscle protein. Without actin, muscles could not contract. Actin binding proteins, like TB-4, sequester actin monomers, the individual units of actin, so that they are protected from degradation and are available for polymerization into microfilaments when needed.
TB-500 and Neurologic Function
Research in rats has found that TB-500 encourages central and peripheral nervous system tissues to undergo repair and remodeling following injury. Though the exact mechanism has yet to be elucidated, the research indicates that TB-500 activates the cells that support neurons. These cells, called oligodendrocytes, keep neurons healthy. Boosting their activity actually improves blood vessel and neuron growth in brain regions that have been damaged, a significant laboratory result that is reflected in clinically significant improvements in behavior, motor control, and cognitive measurements.
Recent research shows that TB-500 can reduce oxidative stress following spinal cord injury and help transplanted neural stem/progenitor cells (NSPCs) to survive long enough to enhance spinal regeneration. These findings could make TB-500 and other TB-4 derivatives of great use in treating severe spinal cord injury. TB-500 may offer critical insight into spinal recovery that allows paralyzed individuals to regain use of affected body regions.
TB-500 and Blood Vessel Growth
TB-500 and TB-4 are potent stimulators of VEGF expression. VEGF is an important signaling molecule in the growth of capillaries (small blood vessels), which are critical to everything from wound healing to hair growth. It is thought that the role of TB-500 is more complicated than this, however. Scientists speculate that the peptide likely underpins a number of steps in the process of blood vessel growth including extracellular matrix remodeling, vasculogenesis, angiogenesis, and the transition of more primitive mesenchymal tissue to the specialized endothelial tissue that lines blood vessels. This speculation is valid because loss of TB-4 has been shown to interfere with blood vessel growth and stability while exogenous administration improves capillary formation and the recruitment of pericytes following injury.
TB-500 and Hair Growth
The discovery that TB-500 improves hair growth happened by accident. When mice that were genetically deficient in TB-4 were shaved for laboratory experiments, it was observed that their hair grew back much slower than wild-type mice. When these same scientists investigated hair growth in mice that were genetically modified to produce increased levels of TB-4, they found that their hair grew back much faster than normal. Under the microscope, these mice show increased numbers of hair shafts and grouped hair follicles.
TB-500 and Antibiotic Synergy
Multi-drug resistance is becoming increasingly common in a number of infections, rendering current therapy ineffective. Unfortunately, there are very few new antibiotics in the pipeline and the process of drug development can take upwards of twenty years on average. A recent study on the effects of TB-4 and its adjuvants, however, provides some hope. Studies of mice suffering from a Pseudomonas aeruginosa infection of the eye have found that TB-4 combined with ciprofloxacin, a standard antibiotic for treating Pseudomonas aeruginosa, increases the effects of the antibiotic, improves healing, reduces inflammation, and promotes faster recovery. The results of just five days of combined therapy showed decreased numbers of colony forming units (CFUs), decreased neutrophil count, and decreased levels of inflammatory reactive oxygen species. This is the first study to demonstrate that TB-500 and similar peptides might be used to promote and enhance the effects of antibiotics.

TB-500 and Cardiovascular Health
Two decades of research have shown that TB-4 and its derivatives have a number of beneficial effects in the cardiovascular and renal systems. The exact mechanisms of these positive contributions are not clearly understood, however. Research suggests that the benefits are actually due to several mechanisms. First, TB-500 promotes the growth of collateral blood vessels, which is useful both as a preventative and in restoring function following disease. Second, TB-500 encourages endothelial cell migration and myocyte survival following a heart attack. Finally, it appears that TB-500 works in concert with other natural signaling molecules to reduce inflammation and reduce fibrosis (scar formation).
Recently, research into hydrogels containing a combination of collagen and TB-4 has shown the peptide promotes angiogenesis and epicardial heart cell migration, thus boosting rates of recovering following ischemia and helping to prevent long-term complications by reducing scarring.
TB-500 and Neurodegenerative Diseases
Progress in finding a treatment for neurodegenerative diseases like Alzheimer's and prion disease has been slow at best. A recent study into the effects of TB-4 on the ability of the immune system to deal with prion protein has shown that the peptide enhances autophagy. Autophagy is the central nervous system's primary protective mechanism against neurodegenerative diseases. The ability of TB-4 to enhance this natural immunity is the first progression toward real treatment of these debilitating diseases in a long time.
TB-500 Summary
TB-500 exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. TB-500 for sale at Volta Peptides is limited to educational and scientific research only, not for human consumption. Only buy TB-500 if you are a licensed researcher.
Article Author
B.S. in molecular biology.
Scientific Journal Author
Co-discoverer of the thymosins. Author of over 400 scientific articles, inventor on more than 15 U.S. Patents. Chairman of the Board of RegeneRx Biopharmaceuticals. B.S. from Wagner College (1959), M.S. and Ph.D. from Rutgers University (1964).
Referenced Citations
- 1P. Cheng, F. Kuang, H. Zhang, G. Ju, and J. Wang, "Beneficial effects of thymosin beta-4 on spinal cord injury in the rat," Neuropharmacology, vol. 85, pp. 408-416, Oct. 2014.
- 2M. Chopp and Z. G. Zhang, "Thymosin beta-4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases," Expert Opin. Biol. Ther., vol. 15 Suppl 1, pp. S9-12, 2015.
- 3H. Li, Y. Wang, X. Hu, B. Ma, and H. Zhang, "Thymosin beta 4 attenuates oxidative stress-induced injury of spinal cord-derived neural stem/progenitor cells through the TLR4/MyD88 pathway," Gene, vol. 707, pp. 136-142, May 2019.
- 4K. N. Dube and N. Smart, "Thymosin beta-4 and the vasculature: multiple roles in development, repair and protection against disease," Expert Opin. Biol. Ther., vol. 18, no. sup1, pp. 131-139, 2018.
- 5D. Philp et al., "Thymosin beta 4 induces hair growth via stem cell migration and differentiation," Ann. N. Y. Acad. Sci., vol. 1112, pp. 95-103, Sep. 2007.
- 6T. W. Carion et al., "Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis," Cells, vol. 7, no. 10, Sep. 2018.
- 7K. M. Kassem, S. Vaid, H. Peng, S. Sarkar, and N.-E. Rhaleb, "Tbeta-4-Ac-SDKP pathway: Any relevance for the cardiovascular system?," Can. J. Physiol. Pharmacol., pp. 1-11, Mar. 2019.
- 8A. D. Shaghiera, P. Widiyanti, and H. Yusuf, "Synthesis and Characterization of Injectable Hydrogels with Varying Collagen-Chitosan-Thymosin beta-4 Composition for Myocardial Infarction Therapy," J. Funct. Biomater., vol. 9, no. 2, Mar. 2018.
- 9H.-J. Han, S. Kim, and J. Kwon, "Thymosin beta 4-Induced Autophagy Increases Cholinergic Signaling in PrP (106-126)-Treated HT22 Cells," Neurotox. Res., Dec. 2018.
- 10Song, Ran et al., "Association between serum thymosin beta-4 levels of rheumatoid arthritis patients and disease activity and response to therapy," Clinical rheumatology, vol. 31, pp. 1253-8, 2012.
- 11Philp, D., et al. "Thymosin beta-4 Promotes Angiogenesis, Wound Healing, and Hair Follicle Development." Mechanisms of Ageing and Development, vol. 125, no. 2, Feb. 2004, pp. 113-115.
Disclaimer
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are furnished for in-vitro studies only. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.
Related Research News
TB-500 and the Brain: Thymosin Beta-4 in Neurological Research
Explore the preclinical evidence for TB-500 (Thymosin Beta-4) in neurological research, including mechanisms, limitations, and safety.
TB-500 vs BPC-157: Evidence, Dosing, Safety Compared
This reference compares TB-500 and BPC-157 across mechanism, dosing, evidence, safety, and pharmacokinetics, highlighting the thin comparative evidence and the need for further study.
Thymosin Beta-4: Neuropathy, Senescence, and Regenerative Research – A Scientific Review
Thymosin Beta-4 research in neuropathy, senescence, and regenerative medicine. Preclinical evidence, mechanisms, and safety review.







